Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...
TipRanks on MSN
Certara appoints Jon Resnick as new CEO
Certara ( ($CERT) ) has provided an update. On December 11, 2025, Certara, a leader in model-informed drug development, announced the appointment ...
Physiomics ( ($GB:PYC) ) has shared an announcement. Physiomics plc announced a new contract with Numab Therapeutics AG to support the ...
Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
The Congressional Budget Office (CBO) informs Congress about the costs or revenue changes associated with proposed legislation, a challenging enough task on its own. Sometimes, the CBO is asked to ...
Simulations Plus, Inc. (NASDAQ: SLP) shares lost ground Thursday. The company, a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced ...
NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback